1.
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
by Tameris, Michele D, Dr
The Lancet (British edition), 2013, Vol.381 (9871), p.1021-1028
2.
Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis -based vaccine to enter clinical trials
by Arbues, Ainhoa
Vaccine, 2013, Vol.31 (42), p.4867-4873
3.
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults
by Luabeya, Angelique Kany Kany
Vaccine, 2015, Vol.33 (33), p.4130-4140
4.
Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting
by Penn-Nicholson, Adam
Vaccine, 2015, Vol.33 (32), p.4025-4034
5.
6.
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis -specific T-cell responses in human
by van Dissel, Jaap T
Vaccine, 2014, Vol.32 (52), p.7098-7107
7.
8.
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials
by Norrby, Maria
Vaccine, 2017, Vol.35 (12), p.1652-1661
9.
10.
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial
by Geldenhuys, Hennie
Vaccine, 2015, Vol.33 (30), p.3592-3599
11.
12.
13.
14.
Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
by Meyer, Joel
Vaccine, 2012, Vol.31 (7), p.1026-1033
15.
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
by Pathan, Ansar A
Vaccine, 2012, Vol.30 (38), p.5616-5624
16.
17.
Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates
by Larsen, Michelle H
Vaccine, 2009, Vol.27 (34), p.4709-4717
18.
Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial
by Thacher, Eleonora G
AIDS (London), 2014, Vol.28 (12), p.1769-1781
19.
Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI
by Vilaplana, C
Vaccine, 2009, Vol.28 (4), p.1106-1116
20.
The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses
by Kagina, Benjamin M.N
Vaccine, 2014, Vol.32 (45), p.5908-5917
